vTv Therapeutics (VTVT) Announces Initiation of Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
Tweet Send to a Friend
vTv Therapeutics Inc. (NASDAQ: VTVT) announced today the initiation of simplici-T1, an adaptive Phase1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
